Prelude Therapeutics Incorporated (PRLD)

NASDAQ: PRLD · IEX Real-Time Price · USD
5.16
-0.10 (-1.90%)
At close: Jul 19, 2024, 4:00 PM
5.13
-0.03 (-0.58%)
After-hours: Jul 19, 2024, 4:07 PM EDT
-1.90%
Market Cap 283.44M
Revenue (ttm) n/a
Net Income (ttm) -125.55M
Shares Out 54.93M
EPS (ttm) -1.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 357,734
Open 5.26
Previous Close 5.26
Day's Range 4.73 - 5.33
52-Week Range 1.66 - 6.72
Beta 1.54
Analysts Hold
Price Target 5.25 (+1.74%)
Earnings Date Aug 1, 2024

About PRLD

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clin... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 25, 2020
Employees 128
Stock Exchange NASDAQ
Ticker Symbol PRLD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for PRLD stock is "Hold." The 12-month stock price forecast is $5.25, which is an increase of 1.74% from the latest price.

Price Target
$5.25
(1.74% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

Combining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance the anti-tumor activity of either agent because of the complementary nature of the two m...

12 days ago - GlobeNewsWire

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in ...

6 weeks ago - GlobeNewsWire

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will partic...

2 months ago - GlobeNewsWire

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024

2 months ago - GlobeNewsWire

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses

3 months ago - GlobeNewsWire

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

WILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that three posters with preclinical ...

4 months ago - GlobeNewsWire

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

WILMINGTON, Del., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will parti...

5 months ago - GlobeNewsWire

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024

5 months ago - GlobeNewsWire

Prelude Therapeutics Announces $25 Million Private Placement

WILMINGTON, Del., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced a privat...

7 months ago - GlobeNewsWire

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

Prioritization of its first-in-class SMARCA2 degrader and potentially best-in-class CDK9 inhibitor programs for continued clinical development Enters partnership with AbCellera to develop a portfolio ...

9 months ago - GlobeNewsWire

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, announces multiple clinical an...

10 months ago - GlobeNewsWire

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will particip...

11 months ago - GlobeNewsWire

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Four lead programs on track to deliver clinical data and to inform future development plans Recent equity financing extends cash runway into 2026,  enabling advancement of Prelude's pipeline through c...

1 year ago - GlobeNewsWire

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

WILMINGTON, Del., May 31, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will partic...

1 year ago - GlobeNewsWire

Prelude Therapeutics Announces Launch of Proposed Public Offering

WILMINGTON, Del., May 17, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or the “Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that it h...

1 year ago - GlobeNewsWire

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

Eight abstracts presented at AACR 2023 demonstrate progress of the pipeline Cash runway unchanged, supporting operations into the fourth quarter of 2024 WILMINGTON, Del., May 08, 2023 (GLOBE NEWSWIRE)...

1 year ago - GlobeNewsWire

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

WILMINGTON, Del., April 27, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will partici...

1 year ago - GlobeNewsWire

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline Eight Abstracts Demonstrate Progress of Prelude's Differentiated Pipeline

1 year ago - GlobeNewsWire

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Four differentiated clinical compounds progressing through Phase 1 towards key data milestones

1 year ago - GlobeNewsWire

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

WILMINGTON, Del., March 15, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial collabora...

1 year ago - GlobeNewsWire

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will parti...

1 year ago - GlobeNewsWire

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

FDA clearance of two new INDs: PRT3789 (First-in-class Selective SMARCA2 degrader) and PRT3645 (next generation CDK4/6 inhibitor)

1 year ago - GlobeNewsWire

Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

Prelude Announces Acceptance of IND For a Differentiated and Brain Penetrant CDK4/6 inhibitor PRT3645 by the US Food and Drug Administration (FDA)

2 years ago - GlobeNewsWire

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

Prelude remains on track for clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 in 2H2022

2 years ago - GlobeNewsWire

Prelude Therapeutics Reports Full Year 2021 Financial Results

Significant progress achieved in 2021: Pipeline now includes six internally discovered small molecule compounds targeting clinically validated pathways in cancers with underserved patients

2 years ago - GlobeNewsWire